【Product for Licensing】siRNA Therapeutics Targeting Nav1.7 for Chronic Pain

If you are interested in this asset or need more information, please kindly contact DrugTimes BD Team at BD@drugtimes.cn, we will present the non-confidential deck to you for review asap

Product Introduction

Nav1.7 is a voltage-gated sodium channel that plays a significant role in pain transmission, making it a potential target for chronic pain treatment. The Nav1.7-targeting siRNA product is an innovative analgesic therapy with long-lasting effects, reportedly providing pain relief for 4-6 months with a single injection. This product is primarily aimed at chronic pain conditions, including osteoarthritis and cancer pain.

Market Size

  • Global Market: According to Evaluate Pharma and BCG analysis, the global small nucleic acid market is expected to reach $8.6 billion by 2024, with a compound annual growth rate (CAGR) of 35% from 2018 to 2024. Another study predicts that the siRNA therapeutics market will grow from $12.7 billion to $39.2 billion by 2029, with a CAGR of approximately 25.3%.
  • Chinese Market: The siRNA drug market in China reached about 1.5 billion yuan in 2023 and is expected to expand to 2.5 billion yuan by 2025, with a CAGR of about 18%. The Chinese analgesic drug industry market size was about 122.6 billion yuan in 2022, with a year-on-year increase of 5.64%.

Transactions

  • Recently, there has been a flurry of BD transactions in the siRNA track, involving multinational pharmaceutical giants such as Novartis and Boehringer Ingelheim. The total transaction value of one deal is over 4 billion US dollars.

Competitive Landscape

  • Globally, key players in the siRNA drug industry include Novartis.
  • In China, market competition mainly focuses on products with and without GalNAc conjugation.

In summary, the Nav1.7-targeting siRNA product shows great potential and rapid growth trends in both the global and Chinese markets, and at the same time, market competition is becoming increasingly fierce, with multiple pharmaceutical giants and innovative companies actively positioning themselves in this field.

If you are interested in this asset or need more information, please kindly contact DrugTimes BD Team at BD@drugtimes.cn, we will present the non-confidential deck to you for review asap.

发布者:DrugTimes001,转载请首先联系contact@drugtimes.cn获得授权

(0)
打赏 为好文打赏 支持药时代 共创新未来! 为好文打赏 支持药时代 共创新未来!
上一篇 2024年12月25日 16:59
下一篇 2024年12月26日 10:23

相关推荐

公众号
公众号
分享本页
返回顶部